FibroBiologics (FBLG) Stock Overview
A clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
FBLG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
FibroBiologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$1.53 |
| 52 Week Low | US$0.18 |
| Beta | -0.67 |
| 1 Month Change | -25.33% |
| 3 Month Change | -21.04% |
| 1 Year Change | -79.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.32% |
Recent News & Updates
Shareholder Returns
| FBLG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -22.6% | -0.7% | -1.9% |
| 1Y | -79.3% | 21.6% | 14.4% |
Return vs Industry: FBLG underperformed the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: FBLG underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| FBLG volatility | |
|---|---|
| FBLG Average Weekly Movement | 19.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: FBLG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FBLG's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Pete O’Heeron | fibrobiologics.com |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers.
FibroBiologics, Inc. Fundamentals Summary
| FBLG fundamental statistics | |
|---|---|
| Market cap | US$14.87m |
| Earnings (TTM) | -US$18.65m |
| Revenue (TTM) | n/a |
Is FBLG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBLG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.65m |
| Earnings | -US$18.65m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FBLG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 12:44 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FibroBiologics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Matthew Caufield | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |